Genetic Technologies Limited (ASX:GTG)


right-arrow Created with Sketch. 0.001 (25%)
MCAP $36.93M
Last trade 14.47pm 28/01/2022 20mins delayed

Latest Announcements

27/01/2022GTGGenetic Technologies Limited
21/01/2022GTGGenetic Technologies Limited
19/01/2022 Price SensitivePSGTGGenetic Technologies Limited
10/01/2022GTGGenetic Technologies Limited
21/12/2021 Price SensitivePSGTGGenetic Technologies Limited
01/12/2021GTGGenetic Technologies Limited
24/11/2021GTGGenetic Technologies Limited
24/11/2021GTGGenetic Technologies Limited

Company Overview

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company focuses on the development and commercialization of genetic risk assessment technology for contracting cancer and other chronic diseases. The Company operates through two geographic segments: Australia and United states of America (USA). Australia segment is the home country of the parent entity and the location of the Company's genetic testing and licensing operations. USA segment is the home of Phenogen Sciences Inc. and GeneType Corporation. The Company’s products include GeneType for Breast Cancer is a test that can determine a woman's risk of developing sporadic breast cancer over a period of time; GeneType for Colorectal Cancer is a test that can determine a patient's risk of developing colorectal cancer over a period of time. The Company focuses on development its Germline testing division for hereditary testing.

GTG in the news

Genetic Technologies Limited (GTG) reports a ‘momentum building’ Q2 FY22 with notable…
Genetic Technologies (GTG) acquires EasyDNA for around $5.4 million in cash and…
Genetic Technologies (GTG) has officially launched its COVID-19 Serious Disease Risk Test…
Genetic Technologies (GTG) has signed a three-year agreement with Infinity BiologiX to…

Search Previous Announcements